Victor is an Honorary Research Associate at IIPP.
His clinical training has taken him from urban Chicago to rural West Bengal, India to the townships of Cape Town, South Africa. As a social scientist, he has researched the political economy of drug development and treatment access through the cases of hepatitis C and multi-drug resistant tuberculosis.
He is a co-founder and served as Executive Director of GlobeMed, a network of students now at over 50 university campuses partnering with communities around the world to improve health of people living in poverty.
Victor is also a Paul and Daisy Soros New American fellow at Northwestern University’s Feinberg School of Medicine.
Victor’s research into the political economy of biomedical innovation investigates the financing, valuation and accessibility of new technologies for health.
He has published on the influence of financialisation in drug pricing and treatment access. He is currently studying the valuation practices used by an array of economic actors in drug development.
Much of this research has focused on new breakthrough medicines for hepatitis C. Victor also explores organisational experiments that aim to bring public health and human rights from the margins to the centre of innovation strategies.
Victor will be leading IIPP’s work on how health innovation can be more mission-oriented to realise therapeutic and public health advances that ensure accessibility for patients and health systems.
- Roy, Victor and Lawrence King. 2016. Betting on Hepatitis C: How Financial Speculation in Drug Development Influences Access to Medicines. BMJ 354:i3718.
- Roy, Victor and Lawrence King. 2016. A Focus on Acquisitions and Buybacks. BMJ i3718.
- Roy, Victor, David Chokshi, Stephen Kissler, and Prabhjot Singh. 2016. Making Hepatitis C a Rare Disease in the United States. Health Affairs.
- Roy, Victor, Luke Hawksbee, and Lawrence King. 2016. Factors Influencing Prescription Drug Costs in the United States. JAMA 316(22):2431–31.